Skip to main content
Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China flag China · Delayed Price · Currency is CNY
49.90
-0.85 (-1.67%)
At close: Mar 9, 2026

SHA:688192 Revenue

In the year 2025, Dizal (Jiangsu) Pharmaceutical had annual revenue of 801.14M CNY with 122.60% growth. Dizal (Jiangsu) Pharmaceutical had revenue of 214.83M in the quarter ending December 31, 2025, with 901.58% growth.

Revenue
801.14M
Revenue Growth
+122.60%
P/S Ratio
28.94
Revenue / Employee
940.30K
Employees
985
Market Cap
23.19B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025801.14M441.23M122.60%
Dec 31, 2024359.90M268.61M294.24%
Dec 31, 202391.29M--
Dec 31, 2022---
Dec 31, 202110.29M-17.48M-62.95%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Jiangsu Nhwa Pharmaceutical Co., LTD 6.02B
Zhejiang Huahai Pharmaceutical 8.71B
Jilin Aodong Pharmaceutical Group 2.34B
Hubei Jumpcan Pharmaceutical 6.14B
Chengdu Kanghong Pharmaceutical Group 4.67B
Kangmei Pharmaceutical 5.28B
Tasly Pharmaceutical Group 8.24B
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd 1.25B
Revenue Rankings